Clinical Trial Update: A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the safety and efficacy of imiquimod cream 2.5% in actinic keratosis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Imiquimod cream 2.5% (imiquimod)

Snippet

Sponsor: Actavis Inc. | Conditions: Actinic Keratosis | Phase 3 | Status: COMPLETED | Results posted: 2019-12-13